October 28, 2011
“Questioning the Risk Profile of Selegiline Hydrochloride” Poster exhibit
presented by Dr. Emory at Institute
on
Psychiatric Services Conference, San Francisco. // October 27-30, 2011
May 15-18, 2011
“Questioning the Risk Profile of Selegiline Hydrochloride” Poster exhibit
presented by Dr. Emory at American Psychiatric Associ-
ation Conference, Honolulu.
May 15-18, 2011
May 10, 2011
New Prospective Study: "The use of referenced-EEG (rEEG) in assisting medication
selection for the treatment of depression", C. DeBattista, G. Kinrys, etal, published in Journal
of Psychiatric Research.
Our approach differs from traditional psychiatric practice because we follow the medical model to find clues to any
neurophysiology that may be causing a person’s mental distress. This is done in a step-wise fashion and includes a medical
and neuro-psychiatric assessment, relevant lab tests and an EEG & quantitative EEG.
Medical/Neuro-Psychiatric Assessment: We collect comprehensive information from
each person's medical history, including data that may not be considered significant in current medical, psychiatric or
psychological practice. This knowledge is integrated with physical findings and a mental/cognitive assessment.
Laboratory Tests & EEG/QEEG Procedure:
Each person receives individualized lab
tests
to rule out an unrecognized medical illness.
An EEG is obtained, measured [Quantitative
EEG] and compared to EEG measures in a
database of healthy persons the same
age.
Each person's EEG/QEEG profile is matched
with similar patients who also had a similar
EEG profile and whose
positive medication
responses are already known.
This unique, comprehensive approach
decreases the
incidence of negative responses
to medication and increases the probability that
treatment will be compatible and effective.
CENTURY CITY MEDICAL PLAZA
2080 Century Park East, Suite #1009
Los Angeles, CA 90067
Office phone: (310) 277-7711
Fax: (310) 277-7723
Email:
office@dremory.com